Učitavanje...
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...
Spremljeno u:
| Izdano u: | Indian J Endocrinol Metab |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Medknow Publications & Media Pvt Ltd
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792029/ https://ncbi.nlm.nih.gov/pubmed/27042424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.176351 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|